Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study
Compose a Response to This Article
Other responses
No responses have been published for this article.